Active

OrbiMed

Q: When was OrbiMed last fund created?

OrbiMed last fund was created/launched in 2026-10-16.

General contacts

Investor type

PE / VC

Founded

1998

AUM

$21 000 M

Location

New York, New York, United States

Investment Ticket

$10-50 m

Investment Stage

Seed Pre-seed Series A Series B Late Stage (Series C+)

Region of investment

North America South America Europe Middle East Africa Asia Australia and others

Investor profile last updated: 17 October, 2026

Profile

OrbiMed is a global healthcare investment firm based in New York City, founded over 25 years ago. It boasts a team of over 150 professionals, including 20 partners, bringing diverse expertise in science, medicine, investment, strategy, operations, and finance. With a commitment to build pioneering healthcare companies, OrbiMed's mission is to drive innovation and improve patient outcomes across the world.

OrbiMed invests globally across multiple segments of the healthcare industry, including biopharmaceuticals, medical devices, diagnostics, and digital health, focusing on early to late-stage opportunities. The firm manages approximately $21 billion in assets through private equity funds, public equity funds, and royalty/credit funds. Notable funds include OrbiMed Private Investments X and OrbiMed Asia Partners VI. Its investor base comprises medical institutions, university endowments, foundations, and sovereign wealth funds, reflecting a diversified and strategic partnership network.

OrbiMed's portfolio includes a variety of companies at the forefront of healthcare innovation. Key investments include Avenzo Therapeutics - oncology therapies, ADARx - RNA targeting therapies, Treeline Biosciences - oncology drug discovery, Mirador Therapeutics - precision medicine, and Insmed - biopharmaceuticals focusing on respiratory and rare diseases.

Industry

Life Sciences Technology MedTech AI HealthTech Software Security SaaS Pharmaceuticals Medical Devices Healthcare Services Biotechnology Food and Beverage Foodtech Media and Entertainment Marketing and Advertising

OrbiMed Funds

Name	Type	Industry	Stage	Region	Size	AUM	Launch date
OrbiMed Private Investments VIII	Venture Capital (VC)	Food and Beverage Foodtech Healthcare Services SaaS Security Software HealthTech	Seed	North America Asia	$5-10 m	$1500 M	March 2025
OrbiMed Asia Partners V	Venture Capital (VC)	Food and Beverage Foodtech Healthcare Services Media and Entertainment HealthTech	Seed	North America Asia	$5-10 m	$751 M	October 2023
OrbiMed Private Investments X	Private Equity (PE) Venture Capital (VC)	Food and Beverage Foodtech Healthcare Services Media and Entertainment SaaS Security Software HealthTech Biotechnology Medical Devices Pharmaceuticals Technology	Series B	North America Europe Asia	$5-10 m	$1900 M	October 2023
OrbiMed Royalty and Credit Opportunities Fund V	Fund of funds	Food and Beverage Foodtech Healthcare Services SaaS Security Software HealthTech	Seed Series A Series B	North America Middle East Asia	$5-10 m	$1900 M	August 2025
OrbiMed Royalty and Credit Opportunities IV	Fund of funds	Food and Beverage Foodtech Healthcare Services Marketing and Advertising SaaS Security Software HealthTech	Seed Series A Series B	North America Europe Asia	$5-10 m	$1700 M	October 2023

Contacts

Name

Title

Social Networks

Tal Zaks Partner, Private Equity

Partner, Private Equity

z•••@•••

Clive Wood Venture Partner

Venture Partner

w•••@•••

Upgrade to see contacts

zNpWABLnjd5ly74h zNpWABLnjd5ly74h

zNpWABLnjd5ly74h

[email protected]

zNpWABLnjd5ly74h zNpWABLnjd5ly74h

zNpWABLnjd5ly74h

[email protected]

zNpWABLnjd5ly74h zNpWABLnjd5ly74h

zNpWABLnjd5ly74h

[email protected]

Investment-team contacts for OrbiMed — including verified work emails and LinkedIn profiles — are available to Private Equity List subscribers.
Instant access on the web. Plans from $129/month — see pricing.

Contacts sourced from the firm's website and LinkedIn, re-verified on a rolling cycle. Spot a stale contact, or none at all? Report it — we re-run that firm within 48h and get back to you.

FAQs about OrbiMed

Is OrbiMed a venture capital or private equity firm?

OrbiMed is a venture capital and private equity firm. It backs companies at Seed, Pre-seed, Series A, Series B and Late Stage (Series C+), writing tickets of $10-50 m.

Where is OrbiMed located?

OrbiMed is located in New York, New York, United States.

When was OrbiMed founded?

OrbiMed was founded in 1998.

What sectors and industries does OrbiMed invest in?

OrbiMed invests in companies and startups in Life Sciences, Technology, MedTech, AI, HealthTech, Software, Security, SaaS, Pharmaceuticals, Medical Devices, Healthcare Services, Biotechnology, Food and Beverage, Foodtech, Media and Entertainment, Marketing and Advertising.

What is OrbiMed geographical focus of investments?

OrbiMed invests in companies and startups in North America, South America, Europe, Middle East, Africa, Asia, Australia and others.

At what stages of companies and startups does OrbiMed typically invest in?

OrbiMed invests in companies and startups at Seed, Pre-seed, Series A, Series B, Late Stage (Series C+).

What is the usual amount of OrbiMed investment?

OrbiMed usually invests $10-50 m on average.

What is the amount of assets of under management (AUM) for OrbiMed?

OrbiMed has around $21 000m assets under management.

When was OrbiMed last fund created?

OrbiMed last fund was created/launched in 2026-10-16

What are the contacts of OrbiMed?

OrbiMed can be reached through its website orbimed.com, its LinkedIn page and its X account. Its general enquiries address is [email protected]. Cold-mailing a general inbox rarely reaches a partner, so Private Equity List also lists the investment-team contacts for OrbiMed — names, roles, verified work emails and LinkedIn profiles — available on a Pro plan from $129/month (see pricing). Contacts are sourced from the firm's website and LinkedIn and re-verified on a rolling cycle. Spot a stale contact, or none at all? Report it — we re-run that firm within 48h and get back to you.

Can I access OrbiMed data via API or MCP?

Yes. Every field on this page — profile, funds, investment criteria, portfolio and investment-team contacts — is available programmatically through the Private Equity List REST API and MCP server, so AI assistants such as Claude and ChatGPT can query OrbiMed directly instead of scraping this page. One subscription covers both the web app and machine access — see API & MCP.

When was the OrbiMed profile last updated?

Private Equity List re-verifies investor profiles on a rolling cycle, pulling from the firm's own website and LinkedIn rather than a one-off import. This profile was last updated on 17 October, 2026. Something out of date here? Report it — we re-run that firm within 48h and get back to you.